Madison Vaccines Incorporated said Monday the company has closed on $8 million in financing to move forward with its therapies for prostate cancer.
MVI is working on two vaccines to combat prostate cancer, one of which is in Phase 2 clinical trials. The technology was developed in the lab of UW-Madison medical school professor Douglas McNeel.
Share new hires, promotions and employee accolades with the region's business leaders.
Up-to-the-minute business news, thoughtful analysis and valuable strategic insights for Milwaukee and Southeastern Wisconsin business leaders.
Copyright © 2025 BizTimes - Milwaukee Business News. All Rights Reserved.
Holiday flash sale!
Limited time offer. New subscribers only.
Subscribe to BizTimes Milwaukee and save 40%
Holiday flash sale! Subscribe to BizTimes and save 40%!
Limited time offer. New subscribers only.
